FDA recommends pause of Johnson & Johnson COVID-19 vaccine after blood clot circumstances

The Meals and Drug Administration along with the Facilities for Illness Management and Prevention (CDC) is recommending a pause within the rollout of the Johnson & Johnson COVID-19 vaccine after a number of cases of a extreme blood clot in recipients.

In response to the FDA, there have been six reported circumstances of the uncommon and extreme kind of blood clot in over 6.8 million Johnson & Johnson vaccine recipients.

“Proper now, these opposed occasions look like extraordinarily uncommon,” the company mentioned on Twitter. “Therapy of this particular kind of blood clot is completely different from the remedy that may usually be administered. CDC will convene a gathering of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to additional overview these circumstances and assess their potential significance. FDA will overview that evaluation because it additionally investigates these circumstances.”

Nevertheless, till that overview is accomplished, the FDA is “recommending this pause.”

“That is essential to make sure that the well being care supplier neighborhood is conscious of the potential for these opposed occasions and may plan because of the distinctive remedy required with one of these blood clot,” the FDA mentioned on Twitter.


A ten a.m. press convention is deliberate for Tuesday.

It is a growing story please proceed to verify again for updates.

Leave a Reply

Your email address will not be published. Required fields are marked *